India · Delayed Price · Currency is INR Sharda Cropchem Earnings Call Transcripts
Fiscal Year 2026
-
Q3 and nine-month results showed record PAT, 39% revenue growth in Q3, and strong margin expansion, with Europe and Latin America driving volumes. Guidance remains robust for Q4 and FY 2027, with sustainable margins and continued high CapEx, while the company remains net debt-free and increases dividends.
-
Q2 FY26 saw 20% revenue growth and 35% volume growth, with gross margins up 690 bps to 34.5% and PAT up 75% year-on-year. Management expects strong H2 performance, maintaining EBITDA margin guidance of 15%-18% and robust cash reserves.
-
Q1 FY26 saw 25% revenue growth, 67% EBITDA growth, and 424% PAT growth, led by strong European demand, margin expansion, and forex gains. Management expects 15% revenue growth and 15%-18% EBITDA margin for FY26, with robust cash reserves and increased CapEx planned.
Fiscal Year 2025
-
Q4 and FY25 saw robust revenue and volume growth, especially in agrochemicals, with improved margins and profitability. Management expects 10%-15% growth and margin expansion in FY26, supported by price recovery and strong demand, particularly in Europe and NAFTA.
-
Q3 FY25 saw a 47% revenue increase and 232% EBITDA growth, driven by strong volume gains and margin expansion. Management expects continued high growth and stable margins, with FY25 revenue projected near INR 4,000 crores and robust cash reserves maintained.
-
Revenue grew 34% year-on-year in Q2 FY2025, led by strong agrochemical performance and margin recovery. Management guides for 15%-18% growth for FY2025, with a robust cash position and improved working capital. NAFTA margins were impacted by high-cost inventory, but overall outlook remains positive.
-
Q1 FY2025 saw 23% revenue growth and a return to profitability, led by strong agrochemical volumes, especially in Europe. Management maintains 15%-18% growth and margin guidance for FY2025, with gradual price recovery expected as market conditions normalize.